论文部分内容阅读
目的：观察不同剂量米索前列醇对晚期妊娠促宫颈成熟及引产的有效性。方法：选择有引产指征、无引产及米索前列醇使用禁忌证的单胎、头位及胎膜完整的晚期妊娠孕妇 ７６例，随机分为 Ａ组（阴道置米索前列醇 ２５ μｇ）； Ｂ组（阴道置米索前列醇５０μｇ）；Ｃ组（口服米索前列醇１００μｇ）。 ３组成功率分别为９６．４２％，９５．６５％和９０．００％。用药前宫颈评分与用药次数及产程时间有密切关系。 ３组分娩及新生儿结局比较差异无显著性。结论：２５μｇ米索前列醇阴道置药用于晚期妊娠促宫颈成熟及引产安全有效。
Objective: To observe the effectiveness of different doses of misoprostol in promoting advanced cervical pregnancy and induction of labor. Methods: One hundred and seventy pregnant women with single fetus, head position and intact fetal membranes without induced labor and misoprostol use were randomly divided into group A (vaginal misoprostol 25 μg) ; Group B (vaginal misoprostol 50μg); Group C (oral misoprostol 100μg). The success rates of 3 groups were 96.42%, 95.65% and 90.00% respectively. Cervical score before medication and the number of medication and birth process are closely related. Three groups of childbirth and neonatal outcome was no significant difference. Conclusion: 25μg misoprostol vaginal drug for cervical pregnancy in late pregnancy and induction of labor is safe and effective.